Metadon Abcur (Methadone Hydrochloride)

Methadone binds to mu‑opioid receptors in the central nervous system, acting as a full agonist to produce analgesia and suppress opioid withdrawal. It also blocks NMDA receptors and inhibits reuptake of serotonin and norepinephrine, which contributes to its effectiveness in pain control and dependence treatment.

The appropriate dose of Metadon Abcur is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made according to therapeutic goals and safety considerations.

Safety data for methadone in pregnancy and lactation are limited. It may be used when the benefits outweigh potential risks, but clinicians should closely monitor both mother and infant. Breastfeeding while on methadone is generally permitted under medical supervision, with attention to infant sedation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Methadone is a full mu‑opioid receptor agonist, offering stronger analgesia and a longer half‑life, while buprenorphine is a partial agonist with a ceiling effect on respiratory depression. Choice depends on patient history, treatment setting, and risk profile; methadone may be preferred for high‑dose opioid dependence, whereas buprenorphine is often used when safety concerns are paramount.

Metadon Abcur should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain potency and stability throughout its shelf life.

Metadon Abcur is administered orally, typically as a tablet or liquid taken with water. The exact form and dosing schedule are prescribed by the treating clinician and should be followed precisely to ensure therapeutic effectiveness and safety.

The most serious risks include respiratory depression, especially during treatment initiation or dose escalation, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored closely for signs of slowed breathing, fainting, or irregular heart rhythms, and any concerning symptoms should prompt immediate medical evaluation.

Metadon Abcur is contraindicated in individuals with known hypersensitivity to methadone, those experiencing acute respiratory depression, or patients with uncontrolled severe asthma. Caution is also advised for patients with significant cardiac conduction abnormalities, severe hepatic impairment, or who are taking interacting medications listed under major interactions.